MedTrace Logo

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

NCT05103683 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-02-13

No results posted yet for this study

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

Conditions

Interventions

DRUG

TORL-1-23

antibody drug conjugate (ADC)

Sponsors & Collaborators

  • Translational Research in Oncology

    collaborator OTHER

  • TORL Biotherapeutics, LLC

    lead INDUSTRY

Principal Investigators

  • Nora Ku, MD · TORL Biotherapeutics, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2026-08-31
Completion
2026-11-15
FDA Drug
Yes

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05103683 on ClinicalTrials.gov